Pergolide treatment and cardiac valve pathology: the continuing saga of ergotamine-induced fibrosis

被引：3

作者：

Montastruc, JL ^{[1
]}

Pathak, A ^{[1
]}

Bagheri, H ^{[1
]}

机构：

[1] CHU Toulouse, Serv Pharmacol Clin, Ctr Midi Pyrenees Pharmacovigilance Pharmacoepide, Fac Med, Toulouse, France

来源：

关键词：

D O I：

10.1016/S0035-3787(04)70843-7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：19 / 21

页数：3

共 18 条

[11]

MONTASTRUC JL, 2002, LETT NEUROLOGUE, V6, P98

[12]

*PRESCR ED STAFF, 1998, PRESCR INTERN, V7, P19

[13]

*PRESCR INT, 2002, PRESCRINE INT, V11, P186

[14] VaIvular heart disease in patients taking pergolide [J].

Pritchett, AM ;

Morrison, JF ;

Edwards, WD ;

Schaff, HV ;

Connolly, HM ;

Espinosa, RE .

REDFIELD, MM ;

NICHOLSON, WJ ;

EDWARDS, WD ;

TAJIK, AJ .

[16]

RINNE UK, 1981, LANCET, V1, P44

[17]

ROTHMANN R, 2002, CIRCULATION, V102, P2826

[18]

Serratrice Jacques, 2002, Cardiol Rev, V10, P334, DOI 10.1097/00045415-200211000-00005